HealthDay News — There appears to be no association in between ß-blocker therapy and depression, according to a study published on the web March 15 in Hypertension.
Thomas G. Riemer, M.D., Ph.D., from Humboldt-Universität zu Berlin, and colleagues carried out a systematic critique and meta-evaluation of information from double-blind, randomized controlled trials to assess the threat for psychiatric adverse events (PAEs) or withdrawal of therapy due to PAEs connected to the use of ß-blockers. Odds ratios had been calculated for person PAEs and withdrawal prices for ß-blockers versus placebo or other active remedy. Data had been integrated for 285 eligible research with 53,533 patients.
In 79 % of the research, the threat for bias was determined to be higher. The researchers discovered that depression was the most regularly reported PAE, with a total of 1,600 circumstances, but it did not take place more usually in the course of ß-blocker remedy versus placebo (odds ratio, 1.02 95 % self-confidence interval, .83 to 1.25). There was no association noticed for ß-blocker use with withdrawal for depression (odds ratio, .97 95 % self-confidence interval, .51 to 1.84). For comparisons against active agents, final results had been comparable. Only uncommon dreams, insomnia, and sleep problems had been possibly connected to ß-blocker therapy amongst other PAEs.
“The possible mental health side effects of ß-blockers have been the subject of discussion in the scientific community for many decades,” a coauthor mentioned in a statement. “So, our results showing ß-blockers are not the cause of so many of these negative side effects are quite consequential.”
One author disclosed economic ties to the pharmaceutical business.
Abstract/Full Text (subscription or payment may be required)
